Benzinga
Benzinga
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Benzinga
lunes, septiembre 14
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Takeda Pharmaceutical Co Ltd
TAK
NYSE
Lista de seguimiento
Get Report
Trade with Public
Get Report
Trade with Public
$18.60
0.34
1.86%
al cierre: Sep 14, 5:00 PM EST
$18.60
N/A
After hour: 4:00 PM EST
Get Report
Panorámica general
Noticias
Previsión de beneficios
Eventos
Finanzas
Sentimiento
Propiedad
Dividendos
Comparar
Opciones
Informe de acciones
Takeda Pharmaceutical Co Financials
Takeda Pharmaceutical Co (TAK) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
CORRECTION: Takeda Pharmaceutical Co Affirms FY2026 Adj EPS Guidance of $3.01 vs $1.57 Est; Affirms FY2026 Sales Guidance of $29.585B vs $28.950B Est
Takeda Pharmaceutical Co (NYSE:TAK) affirms FY2026 Adj EPS guidance from $3.01 to $3.01 vs $1.57 analyst estimate. Affirms FY2026 sales outlook from $29.585 billion to $29.585 billion vs $28.950 billion estimate.
Benzinga Newsdesk
PRO
Takeda Pharmaceutical Co Affirms FY2026 GAAP EPS Guidance of $0.66; Affirms FY2026 GAAP Sales Guidance of $29.585B
Takeda Pharmaceutical Co (NYSE:TAK) affirms FY2026 GAAP EPS guidance from $0.66 to $0.66. Affirms FY2026 sales outlook from $29.585 billion to $29.585 billion.
Benzinga Newsdesk
PRO
Takeda Pharmaceutical Q1 Adj. EPS $0.48 Beats $0.39 Estimate, Sales $7.655B Beat $7.060B Estimate
Takeda Pharmaceutical (NYSE:TAK) reported quarterly earnings of $0.48 per share which beat the analyst consensus estimate of $0.39 by 23.08 percent. This is a 7.69 percent decrease over earnings of $0.52 per share from
Benzinga Newsdesk
Takeda's Next Wave Of Drugs Has Investors Watching Closely
Takeda eyes growth with FDA Priority Reviews for narcolepsy and PV drugs. Get the latest on TAK's late-stage pipeline and 2026 forecasts.
Vandana Singh
Earnings Scheduled For May 13, 2026
Benzinga Insights
PRO
Takeda Pharmaceutical Co Sees FY2026 GAAP EPS $0.66.
Takeda Pharmaceutical Co (NYSE:TAK) is looking for FY2026 GAAP EPS of $0.66.
Benzinga Newsdesk
Privacy Manager